|Articles|September 12, 2022
Why eConsent Primes Studies & Patients for Success
Author(s)Medable
According to a survey conducted by Florence Healthcare, 47% of research sites had adopted eConsent by December 2020, just 8 months after the WHO declared an official pandemic. By July 2021, 75% of research sites had either used it or were looking into it. In conclusion - a decentralized consent process is here to stay. Learn why Medable's Total eConsent offering is the industry-leading remote consent technology, and how it can reduce your enrolment timelines by 50%.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
Trending on PharmExec
1
Vinay Prasad Out at CBER for Second Time in Under a Year
2
Key Factors Contributing to Uncertainty in Moderna's mRNA Vaccine Review
3
Ipsen Withdraws Tazverik from Market Due to Emerging Data from Clinical Trial
4
Novo Nordisk Signs Deal with Hims & Hers
5